<DOC>
	<DOCNO>NCT00975741</DOCNO>
	<brief_summary>Mometasone furoate ( MF ) new potent synthetic corticosteroid . Internationally , MF administer breath-actuated DPI supply multidose device . Capsules administer monodose device would offer alternative MF DPI multidose treatment term cost-effectiveness develop Brazil . The aim present non-inferiority clinical study evaluate device term efficacy safety .</brief_summary>
	<brief_title>Efficacy Safety Two Dry Power Inhalers ( DPIs ) Used Application Mometasone Treatment Asthma</brief_title>
	<detailed_description>Background : Internationally , MF administer breath-actuated DPI supply multidose device . Capsules administer monodose device would offer alternative MF DPI multidose treatment term cost-effectiveness develop Brazil . Results laboratory analysis respirable fraction , content uniformity emit dose bulk powder percentage particle &lt; 1 micra MF 200 µg MF 400 µg capsule indicate equivalent performance comparison MF DPI multidose . Aim : The aim present non-inferiority clinical study evaluate device term efficacy safety . Methods : Ninety-seven adult patient moderate persistent asthma randomize two group receive 60 day dose 400 µg DPI MF daily ( even ) use multidose monodose device . Follow-up visit schedule Days 7 , 14 , 28 , 42 56 . Efficacy assess mean pulmonary function test ( spirometry - FEV1 PEFR ) visit . In addition , subject record twice daily PEFR , symptom score use rescue medication throughout study . Response therapy also assess . Safety evaluation include monitoring adverse event , vital sign , clinical laboratory test ( plasma cortisol concentration assess enrollment repeat 60 day MF treatment ; cortrosyn test perform enrollment 60 day MF treatment ) , physical examination .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>A diagnosis asthma least 6 month Baseline FEV1 must &gt; = 55 % &lt; = 85 % predicted Increase absolute FEV1 &gt; 12 % , absolute volume increase least 200 mL reversibility test Use adequate form birth control nonpregnant woman childbearing potential Absence use follow medication prior inclusion : Beta 2 agonist shortacting ( inhale , oral ) 12 Hours Beta 2 agonist longacting ( inhale ) 48 Hours Ipratropium bromide12 hour Cromolyn sodium , nedocromil07 day Astemizole03 month Cetotifeno03 month Another investigational drug01 month Theophyline2 week Antihistamines07 day Anticholinergics07 day Leukotriene modifiers2 week Oral decongestant longacting72 hour Oral decongestant shortacting24 hour Women pregnant , breastfeeding , premenarcheal . Subjects use investigational drug within last 30 day Subjects receive immunotherapy Subjects require use &gt; 12 puff per day Salbutamol 2 consecutive day Smokers exsmokers Subjects allergic corticosteroid betaagonists Subjects require inpatient hospitalization asthma control within previous 3 month Subjects require ventilator support respiratory failure secondary asthma within last 5 year Subjects treat emergency room ( severe asthma exacerbation ) , admit hospital management airway obstruction , two occasion within last six month Subjects clinical evidence emphysema , chronic bronchitis , bronchiectasis , cystic fibrosis Subjects significant history renal , hepatic , cardiovascular , metabolic , neurologic , hematological , respiratory , gastrointestinal , cerebrovascular , significant medical illness disorder , judgment investigator , could interfere study , require treatment might interfere study Subjects experience upper low respiratory tract infection ( viral bacterial ) within previous 2 week prior enrollment Subjects clinically significant abnormality chest xray Screening Visit within previous year Subjects know HIV positive Subjects know illicit drug abuser Subjects hypothalamicpituitaryadrenal ( HPA ) axis disturbance Subjects severe pulmonary airflow obstruction show lifethreatening characterized cyanosis , confusion , somnolence , coma tiredness , thorax silent hear show weak respiration , PEFR &lt; 25 % predict normal , bradycardia ( heartbeat bellow 60 beat per minute ) Subjects baseline FEV1 &lt; 55 % predict normal Subjects uncontrolled hypertension Subjects suspect pneumonia , pneumothorax , pneumomediastinum , pulmonary tuberculosis , alpha1 antitrypsin deficiency , lung mycosis ( blastomycosis , histoplasmic ) pulmonary cystic fibrosis Subjects history thoracic surgery previous malignancy lung Subjects significant heart disease ( e.g. , previous acute myocardial infarction , angina pectoris , pulmonary edema cardiovascular disease characterize lifethreatening Subjects receive betaadrenergic blocking agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Mometasone furoate</keyword>
	<keyword>Inhalation device</keyword>
	<keyword>Forced expiratory volume</keyword>
</DOC>